What is Pitobrutinib/Pitobrutinib? This article will take you into this new drug!

Pirtobrutinib is a new type of kinase inhibitor mainly used to treat certain types of B-cell malignancies, especially in patients with previous treatment failure or disease recurrence, showing unique clinical advantages. It belongs to the Bruton's tyrosine kinase (BTK) inhibitor class of drugs and is the first non-covalent BTK inhibitor approved by the FDA. Unlike traditional covalently bound BTK inhibitors (such as ibrutinib), pitobrutinib can bind to BTK in a reversible manner. Even if the BTK protein is mutated at the Cys481 site, the drug can still maintain an effective inhibitory effect, thereby overcoming the resistance problem faced by the first generation of BTK inhibitors.

According to FDA approval, pitobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after receiving at least two systemic treatment regimens (including BTK inhibitors). At the same time, it is also suitable for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two treatment regimens including BTK inhibitors and BCL-2 inhibitors. These indications are based on the good efficacy and safety of the drug in drug-resistant populations in clinical studies.

In terms of its mechanism of action, pitobrutinib highly selectively inhibits theBTK signaling pathway, thereby interfering with the survival and proliferation signals of B cells and combating the continued expansion of malignant B cells. It can not only effectively control the progression of the disease, but also improve patients' symptoms and quality of life. In addition, the drug has high target selectivity and few off-target effects, so the adverse reactions are generally mild and well tolerated. The medication is taken orally, which is helpful for patients to adhere to treatment for a long time.

With the deepening of clinical research, pitobrutinib is being explored for moreB cell-related tumors, and may be used in combination with other targeted drugs or immunotherapy to become one of the core drugs in the field of precision treatment of hematological tumors in the future. For patients with limited treatment options and strong drug resistance in the past, the advent of pitobrutinib undoubtedly provides new treatment hope.

Reference materials:https://go.drugbank.com/drugs/DB17472